HL
0000-0001-8545-3292 Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (28)
- Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors Save
- Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis Save
- Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1 Save
- A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma Save
- Antibody–drug conjugates in hematologic malignancies Save
- A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis Save
- Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy Save
- Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel Save
- The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis Save
- A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis Save
- Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry Save
- Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study Save
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma Save
- Data from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma Save
- Data from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma Save
- Supplementary Figure from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma Save
- Supplementary Figure from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma Save
- Supplementary Table from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma Save
- Supplementary Table from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma Save
- Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography–tandem mass spectrometry Save